Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ACP3 | P15309 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL27919184 | 0.98 | CYP1A2 (0.55) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL30365968 | 0.98 | CYP1A2 (0.59) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL47 | 0.98 | CYP1A2 (0.59) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL28214959 | 0.95 | CYP1A2 (0.57) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| Iodide SCHEMBL27636636 | 0.95 | CYP1A2 (0.57) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| Hydrogen Sulfide SCHEMBL28763519 | 0.95 | CYP1A2 (0.57) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL29140496 | 0.95 | CYP1A2 (0.57) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| Water SCHEMBL28258264 | 0.95 | CYP1A2 (0.57) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| Naphthalene SCHEMBL28758695 | 0.95 | CYP1A2 (0.57) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| Water SCHEMBL8463988 | 0.95 | CYP1A2 (0.57) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111410611-A | Preparation method of (R) -1- (1-naphthyl) -2 ethylamine | 宁波赜军医药科技有限公司 | 2020-07-14 | — | — | CN | claimed |
| US-12275752-B2 | Class of phosphine nitrogen ligand with multiple chiral centers and its synthesis method and application | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-15 | — | — | US | disclosed |
| US-20220332739-A1 | A CLASS OF PHOSPHINE NITROGEN LIGAND WITH MULTIPLE CHIRAL CENTERS AND ITS SYNTHESIS METHOD AND APPLICATION | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2022-10-20 | — | — | US | disclosed |
| CN-112079865-B | Phosphine nitrogen ligand with multiple chiral centers and synthetic method and application thereof | 中国科学院上海有机化学研究所 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020248756-A1 | PHOSPHINE NITROGEN LIGAND HAVING MULTIPLE CHIRAL CENTERS, SYNTHESIS METHOD THEREFOR AND USE THEREOF | 中国科学院上海有机化学研究所 | 2020-12-17 | — | — | WO | disclosed |
| CN-112079865-A | Phosphine nitrogen ligand with multiple chiral centers and synthetic method and application thereof | 中国科学院上海有机化学研究所 | 2020-12-15 | — | — | CN | disclosed |
| CN-111410611-A | Preparation method of (R) -1- (1-naphthyl) -2 ethylamine | 宁波赜军医药科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-101426503-A | Compositions and methods of treatment for inhibiting kinase and/or HMG-COA reductase | PHARMIX CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| CN-101103060-A | polyurea compound | NUPLEX RESINS BV (NL) | 2008-01-09 | — | — | CN | disclosed |
| CN-1121854-C | Transdermal device containing polyvinylpyrrolidone as solubility ehancer | NOVEN PHARMA (US) | 2003-09-24 | — | — | CN | disclosed |
| US-6277851-B1 | ORALLY ADMINISTERED TRYPSIN-RELATED SERINE PROTEASE INHIBITORS; ANTICOAGULANTS | ADIR ET COMPAGNIE (FR) | 2001-08-21 | — | — | US | disclosed |
| WO-1999031506-A9 | PARALLEL SOLUTION PHASE SYNTHESIS OF LACTAMS | LILLY CO ELI (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5631401-A | Inhibitors of protein farnesyltransferase and squalene synthase | ABBOTT LABORATORIES (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| US-4091211-A | ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4009181-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIRHEUMATIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-4005073-A | ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1977-01-25 | — | — | US | disclosed |
| US-3932482-A | CARDIOTONIC | STERLING DRUG INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275752-B2 | Class of phosphine nitrogen ligand with multiple chiral centers and its synthesis method and application | ALK, ATIC, PNISR | CYP1A2 3296/4885CYP2C19 2567/4885CYP2D6 4345/4885 |
| US-20220332739-A1 | A CLASS OF PHOSPHINE NITROGEN LIGAND WITH MULTIPLE CHIRAL CENTERS AND ITS SYNTHESIS METHOD AND APPLICATION | ALK, ATIC, PDGFRA | CYP1A2 3280/4885CYP2C19 2709/4885CYP2D6 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.